CoChat

Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes

Kazda, Christof M., Frias, Juan, Foga, Irene, Cui, Xuewei, Guzman, Cristina B., Garhyan, Parag, Heilmann, Cory, Yang, Jihui Anne, Hardy, Thomas A. · 2017 · Diabetes, Obesity and Metabolism
Cited by 39

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Aims: To assess the effect of LY2409021 on systolic blood pressure ( SBP ) in patients with type 2 diabetes. Materials and methods: This 6‐week, randomized, crossover study evaluated the effects of once‐daily administration of LY2409021 20 mg vs those of placebo on SBP , diastolic BP ( DBP ), and mean arterial pressure ( MAP ) using 24‐hour ambulatory BP monitoring ( ABPM ) in 270 subjects treated with diet/exercise ± metformin. Other measures included changes in glycemic control, serum lipids, and hepatic safety markers. Results: At 6 weeks of LY2409021 treatment, 24‐hour mean SBP was increased, with a least squares mean ( LSM ) difference of 2.26 mm H g vs placebo (95% CI : 1.11, 3.40; P < .001). The 24‐hour mean DBP and MAP also increased, with LSM differences of 1.37 mm H g (95% CI : 0.66, 2.08; P < .001) and 1.67 mm H g (95% CI : 0.86, 2.47; P < .001) vs placebo, respectively. At week 6, LY2409021 treatment reduced glycated hemoglobin ( HbA1c ) levels, with an LSM difference of −0.49% (−5.4 mmol/mol) (95% CI : −0.56%, −0.42% [−6.1, −4.6 mmol/mol]; P < .001) vs placebo. Mean HbA1c at baseline was 7.3% (56 mmol/mol). Small but significant changes in serum lipid and aminotransferase levels were observed with LY2409021 treatment (all P < .05 vs placebo). Conclusions: Statistically significant increases in BP , MAP and serum lipid levels were observed with LY2409021 treatment at a dose that lowered HbA1c and glucose levels. These effects may limit the clinical utility of LY2409021 as a chronic treatment for type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12904

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 39

Metadata

Authors
Kazda, C. M., Frias, J., Foga, I., Cui, X., Guzman, C. B., Garhyan, P., Heilmann, C., Yang, J. A., & Hardy, T. A.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2017-03-27
Volume
19
Issue
8
Pages
1071-1077
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2588151434
Cited by
39
References
6
FWCI
3.90
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes. https://app.cochat.ai/papers/10.1111/dom.12904
The paper
Kazda, C. M., Frias, J., Foga, I., Cui, X., Guzman, C. B., Garhyan, P., Heilmann, C., Yang, J. A., & Hardy, T. A. (2017). Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12904

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.